BiotechTube
Home/Rhythm Pharmaceuticals/David Meeker, M.D.
DM

David Meeker, M.D.

Chair, President and Chief Executive Officer

Rhythm Pharmaceuticals

Therapeutic Areas

Rare Genetic Diseases of ObesityNeuroendocrine Diseases

Rhythm Pharmaceuticals Pipeline

DrugIndicationPhase
IMCIVREE® (setmelanotide)Acquired Hypothalamic ObesityPhase 3 / Approved
Bivamelagon (LB54640)Acquired Hypothalamic ObesityPhase 2
RM-718Not Specified (Weekly MC4R agonist)Phase 1

Leadership Team at Rhythm Pharmaceuticals

HS
Hunter Smith
Chief Financial Officer
JL
Jennifer L. Miller, M.D.
Chief Medical Officer
View full Rhythm Pharmaceuticals profile